Editorial Comment to Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer

被引：0
|
作者：
Yuasa, Takeshi [1 ]
机构：
[1] Canc Inst Hosp, Japanese Fdn Canc Res, Dept Urol, Tokyo, Japan
来源：
INTERNATIONAL JOURNAL OF UROLOGY | 2022年 / 29卷 / 01期
关键词：
MEN;
D O I：
10.1111/iju.14725
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：33 / 33
页数：1
相关论文
共 50 条
  • [1] Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer
    Shiota, Masaki
    Blas, Leandro
    Kobayashi, Satoshi
    Matsumoto, Takashi
    Kashiwagi, Eiji
    Takeuchi, Ario
    Inokuchi, Junichi
    Shiga, Ken-ichiro
    Yokomizo, Akira
    Eto, Masatoshi
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 (01) : 26 - 32
  • [2] Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
    Tseng, Chi-Shin
    Yang, Jui-Han
    Huang, Shi-Wei
    Wang, Yu-Jen
    Chen, Chung-Hsin
    Pu, Yeong-Shiau
    Cheng, Jason Chia-Hsien
    Huang, Chao-Yuan
    BMC CANCER, 2023, 23 (01)
  • [3] Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
    Chi-Shin Tseng
    Jui-Han Yang
    Shi-Wei Huang
    Yu-Jen Wang
    Chung-Hsin Chen
    Yeong-Shiau Pu
    Jason Chia-Hsien Cheng
    Chao-Yuan Huang
    BMC Cancer, 23
  • [4] Survival by first-line therapy and prognostic group among men with metastatic castration-resistant prostate cancer
    Caram, Megan E. V.
    Kumbier, Kyle
    Tsao, Phoebe A.
    Burns, Jennifer
    Sparks, Jordan B.
    Stensland, Kristian D.
    Reichert, Zachery R.
    Alumkal, Joshi J.
    Hollenbeck, Brent K.
    Shahinian, Vahakn
    Tsodikov, Alexander
    Skolarus, Ted A.
    CANCER MEDICINE, 2024, 13 (12):
  • [5] Editorial Comment to Survival beyond cabazitaxel for metastatic castration-resistant prostate cancer
    Yamamoto, Yoshiyuki
    Nonomura, Norio
    INTERNATIONAL JOURNAL OF UROLOGY, 2024, 31 (07) : 831 - 832
  • [6] Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
    Armstrong, Andrew J.
    Garrett-Mayer, Elizabeth
    de Wit, Ronald
    Tannock, Ian
    Eisenberger, Mario
    CLINICAL CANCER RESEARCH, 2010, 16 (01) : 203 - 211
  • [7] Survival outcome in patients with metastatic castration-resistant prostate cancer according to first-line treatment
    Thurin, Nicolas H.
    Rouyer, Magali
    Jove, Jeremy
    Gross-Goupil, Marine
    Haaser, Thibaud
    Rebillard, Xavier
    Soulie, Michel
    de Pouvourville, Gerard
    Pierres, Marie
    Capone, Camille
    Lamarque, Stephanie
    Bignon, Emmanuelle
    Droz-Perroteau, Cecile
    Moore, Nicholas
    Blin, Patrick
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 114 - 114
  • [8] Factors influencing survival in metastatic castration-resistant prostate cancer therapy
    Marchioni, Michele
    Marandino, Laura
    Amparore, Daniele
    Berardinelli, Francesco
    Mascitti, Marco
    Ferro, Matteo
    Campi, Riccardo
    Schips, Luigi
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (10) : 1061 - 1079
  • [9] Management of metastatic castration-resistant prostate cancer after first-line docetaxel
    Harrington, J. A.
    Jones, R. J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (14) : 2133 - 2142
  • [10] Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry
    Simon Chowdhury
    Anders Bjartell
    Nicolaas Lumen
    Pablo Maroto
    Thomas Paiss
    Francisco Gomez-Veiga
    Alison Birtle
    Gero Kramer
    Ewa Kalinka
    Dominique Spaëth
    Susan Feyerabend
    Vsevolod Matveev
    Florence Lefresne
    Martin Lukac
    Robert Wapenaar
    Luis Costa
    Targeted Oncology, 2020, 15 : 301 - 315
12345